425: Carisma Therapeutics to Merge with OrthoCellix, Pivoting to Regenerative Cell Therapies for Orthopedic Diseases

Carisma Therapeutics Inc. has entered into a definitive merger agreement with OrthoCellix, Inc., a wholly-owned subsidiary of Ocugen, Inc., in an all-stock transaction that will pivot the combined company's focus to regenerative cell therapies for orthopedic diseases.

Summary

• Carisma Therapeutics Inc. (Carisma) will merge with OrthoCellix, Inc. (OrthoCellix), a wholly-owned subsidiary of Ocugen, Inc., through an all-stock transaction.
• The combined entity will be renamed OrthoCellix, Inc. and is expected to trade on Nasdaq under the ticker symbol OCLX.
• Upon closing, existing Carisma stockholders are expected to own approximately 10.0% of the combined company on a fully-diluted basis, while OrthoCellix's stockholder (Ocugen) and concurrent investment participants will own approximately 90.0%.
• The transaction includes a concurrent private financing of at least $25.0 million, with Ocugen committing to purchase at least $5.0 million of Carisma Common Stock.
• Pre-merger Carisma common stockholders will receive Contingent Value Rights (CVRs) for each outstanding share, representing the right to receive contingent cash payments from the net proceeds of Carisma's legacy assets, including its collaboration and license agreement with ModernaTX, Inc.
• The merger is intended to qualify as a tax-free reorganization for federal income tax purposes.
• The combined company's board of directors is expected to consist of six members, with five designated by OrthoCellix and one by Carisma.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative for existing Carisma shareholders due to significant dilution and a complete pivot away from their original business focus. While the merger provides a path forward for the public entity and a new clinical asset, the terms heavily favor OrthoCellix's existing shareholder (Ocugen).

Positives

• The merger provides Carisma with a strategic pivot into regenerative cell therapies for orthopedic diseases, leveraging OrthoCellix's Phase 3-ready NeoCart technology.
• NeoCart has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and concurrence on a single, confirmatory Phase 3 clinical trial, potentially accelerating its path to market.
• The concurrent investment of at least $25.0 million is expected to fund the combined company to complete the NeoCart Phase 3 trial without additional cost or investment from Ocugen.
• The transaction aims to unlock the market potential of NeoCart and provide value for both Ocugen and Carisma stockholders.
• Carisma's existing shareholders will receive CVRs, offering potential future cash payments from the monetization of Carisma's legacy assets, including its collaboration with ModernaTX, Inc.

Negatives

• Existing Carisma stockholders will experience significant dilution, owning only approximately 10.0% of the combined company post-merger.
• The value of the Contingent Value Rights (CVRs) is highly speculative, with no assurance that holders will receive any payments, as it depends on the successful monetization of Carisma's legacy assets.
• Carisma's valuation for the merger is set at $15.0 million, significantly lower than OrthoCellix's valuation of $135.0 million, indicating a less favorable valuation for Carisma's existing business.

Risks

• Conditions to the closing or consummation of the Proposed Transactions may not be satisfied, including failure to obtain stockholder approvals for the reverse stock split and the merger.
• The proposed concurrent financing may not be completed in a timely manner, or at all.
• Uncertainties exist regarding the timing of the consummation of the Proposed Transactions.
• Risks related to Carisma's continued listing on Nasdaq until closing and the combined company's ability to remain listed post-closing.
• Uncertainties regarding the impact any delay in closing would have on the anticipated cash resources of the combined company, and other unanticipated spending and costs that could reduce cash resources.
• Failure or delay in obtaining required approvals from governmental or quasi-governmental entities.
• The occurrence of any event, change, or circumstance that could lead to the termination of the merger agreement.
• The effect of the announcement or pendency of the merger on Carisma's or OrthoCellix's business relationships, operating results, and business generally.
• Costs related to the merger and unexpected costs, charges, or expenses resulting from the Proposed Transactions.
• Risk that adjustments to the exchange ratio could result in OrthoCellix stockholders and Carisma stockholders owning more or less of the combined company than currently anticipated.
• Risks related to the market price of Carisma's common stock relative to the value suggested by the exchange ratio.
• Uncertainties associated with OrthoCellix's NeoCart portfolio, including clinical development and regulatory approval delays.
• Inability of the combined company to obtain sufficient additional capital to advance product candidates.
• Uncertainties in obtaining successful clinical results for product candidates and unexpected costs.
• Failure to realize any value from product candidates due to inherent risks in bringing them to market.
• Outcome of any legal proceedings against Carisma, OrthoCellix, or their directors/officers related to the Proposed Transactions.
• Ability of Carisma and OrthoCellix to obtain, maintain, and protect intellectual property rights.
• Competitive responses to the Proposed Transactions.
• Potential adverse reactions or changes to business relationships, operating results, and business generally, resulting from the announcement or completion of the Proposed Transactions.
• Changes in regulatory requirements and government incentives.
• Possible failure to realize, or longer than expected time to realize, anticipated benefits of the Proposed Transactions, including future financial and operating results.
• Risk of involvement in litigation, including securities class action litigation, that could divert management attention and harm the business.

Future Outlook

The combined company will focus on developing OrthoCellix's NeoCart technology for knee articular cartilage defects, with plans to initiate a U.S. FDA-endorsed Phase 3 clinical trial by the end of 2025. NeoCart has already received Regenerative Medicine Advanced Therapy (RMAT) designation and FDA concurrence for a single confirmatory Phase 3 trial. The post-transaction capital resources are expected to be sufficient to fund OrthoCellix's pipeline through certain milestones.

Management Comments

• Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen: 'We believe merging OrthoCellix with Carisma will allow us to create a publicly-traded company focused on the development of NeoCart and provide value for both Ocugen and Carisma stockholders while unlocking true market potential of NeoCart.'
• Dr. Shankar Musunuri: 'We believe NeoCart has tremendous potential to deliver a truly transformative approach to cartilage repair, and we’ve established OrthoCellix with dedicated resources to bring this revolutionary technology to the patients who desperately need it.'
• Steven Kelly, President and Chief Executive Officer, of Carisma: 'Carisma evaluated a range of strategic alternatives, and we believe this proposed transaction represents an opportunity to deliver significant value to our stockholders.'
• Steven Kelly: 'OrthoCellix is strongly positioned with its NeoCart platform, a dedication to developing regenerative cell therapies, and a well-credentialed management team to lead the combined company.'

Industry Context

This merger signifies a strategic shift for Carisma Therapeutics from macrophage engineering for fibrosis and cancer to regenerative cell therapies for orthopedic diseases. The combined entity will enter the orthopedic regenerative medicine market, focusing on NeoCart, a first-in-class autologous cartilage implant technology. This aligns with a growing trend in biotech towards specialized, late-stage clinical assets with expedited regulatory pathways like RMAT designation.

Management Changes

Corporate Governance

Legal Proceedings

• The document mentions the risk of involvement in litigation, including securities class action litigation, that could divert management attention and harm the combined company's business.

Related Party Transactions

• Ocugen, Inc. (as the sole stockholder of OrthoCellix) is a key party to the merger agreement and will be the largest shareholder of the combined company.
• Ocugen will commit to a $5.0 million investment as part of the concurrent financing.
• Ocugen contributed the NeoCart Assets to OrthoCellix prior to the merger agreement.
• The combined company will utilize the Good Manufacturing Practice facility established by Ocugen to support OrthoCellix's initial development of NeoCart.
• Transition Services Agreement and Manufacturing and Supply Agreement to be entered into between Ocugen (Guarantor) and OrthoCellix (Company) prior to closing.

Stakeholder Impact

• **Shareholders (Carisma):** Significant dilution (10% ownership in combined entity), but receive CVRs for potential future payments from legacy assets. Strategic shift to a new therapeutic area.
• **Shareholders (Ocugen/OrthoCellix):** Will own approximately 90% of the combined company, gaining a Nasdaq-listed entity for NeoCart development and access to public markets.
• **Employees (Carisma):** Potential for changes in roles and responsibilities due to the strategic pivot and new management structure. Some employees may be terminated as part of winding down legacy business.
• **Employees (OrthoCellix):** Integration into a public company structure, with new equity incentive plans.
• **Customers/Patients:** Potential benefit from the continued development of NeoCart for orthopedic diseases, offering a new regenerative cell therapy option.
• **Creditors:** Carisma's net cash at closing must be at least negative $1,000,000, which is a closing condition, providing some assurance regarding immediate liquidity.

Next Steps

• Carisma to seek stockholder approval for a reverse stock split, issuance of shares for the merger, name change to OrthoCellix, Inc., and adoption of new equity incentive plans.
• Carisma to file a registration statement on Form S-4 with the SEC to register shares issued in the merger.
• OrthoCellix to seek requisite stockholder approval for the merger agreement.
• Carisma to seek to monetize certain legacy assets prior to closing.
• Ocugen to enter into a securities purchase agreement committing to a $5.0 million investment by August 1, 2025.
• OrthoCellix and Carisma to use commercially reasonable efforts to secure the full $25.0 million Concurrent Investment.
• Combined company to initiate a U.S. FDA-endorsed Phase 3 clinical trial for NeoCart by the end of 2025.
• Parent to maintain directors and officers liability insurance policies for six years post-merger.

Key Dates

Keywords

Reverse Merger, Biotechnology, Regenerative Medicine, Orthopedic Diseases, Cell Therapy, NeoCart, Clinical Trials, Phase 3, FDA RMAT Designation, SEC Filing, CARM, OCGN, OCLX, Contingent Value Rights, Private Financing, Stock Dilution